Ibex Medical Analytics

Ibex Medical Analytics is an Israeli insurtech which applys AI, data science, image analysis, and machine learning to medicine, in particular, cancer diagnostics, through its digital platform. Ibex combines data from digitised glass slides and electronic medical records to reveal underlying patterns and extract valuable clinical insights that can transform how pathology and oncology are practiced.

Ibex uses artificial intelligence (AI) to develop clinical-grade algorithms that detect cancer as accurately as a human pathologist. It’s product suite uses the algorithms to analyse images, detect and grade cancer in biopsies, helping pathologists reduce diagnostic error rates and enable a more efficient workflow.

In March 2019 Ibex raised $11m in Series A funding, led by aMoon Fund. The company stated its funding would be used to expand its engineering team and expand its product offering.

In late 2019 Ibex's Second Read system for prostate core needle biopsies diagnosis was deployed at Maccabi Healthcare Services (one of the four Health Maintenance Organisations (HMOs) currently active in Israel) and the company stated it would be rolled out commercially to pathology labs across the country in 2020. Through its strategic collaboration with Maccabi Healthcare Services, Ibex has access to a dataset with millions of pathology slides and EMRs of 2.5 million patients, enabling it to develop algorithms with further improved accuracy levels. This is in addition to collaborations with leading institutes and international hospitals, including Pittsburgh-based UPMC, a world-renowned health care provider, and MediPath, the largest private pathology lab in France.

In March 2021, Ibex Medical Analytics raised a $38m Series B. Originally incubated by AXA's Kamet Ventures, the cash will be used to further develop its AI-powered diagnostic platform and accelerate sales in N. America and Europe.